Clinical trial
Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
NCT00006216 · Louisiana State University Health Sciences Center in New Orleans, Other · Unknown status
Key facts
| NCT number | NCT00006216 |
|---|---|
| Title | Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma |
| Official title | Treatment of Malignant Pleural Mesothelioma With Gene Modified Cancer Cell Lines |
| Lead sponsor | Louisiana State University Health Sciences Center in New Orleans, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Biological, Drug |
| Interventions | PA-1-STK ovarian carcinoma vaccine, ganciclovir |
| Start date | Aug 1, 1997 |
| First posted | Apr 26, 2004 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: